Deutsche Bank AG Purchases New Shares in Omnicell, Inc. $OMCL

Key Points

• Deutsche Bank acquired 49,147 Omnicell shares worth approximately $2.04 million in the second quarter, giving it a 0.11% stake. Institutional investors collectively own 97.70% of the company.
• Analyst sentiment remains broadly positive, with seven Buy ratings, one Hold and one Sell; the consensus rating is “Moderate Buy” with an average price target of $57.86, despite some recent target reductions and a Zacks downgrade to “Strong Sell.”
• Omnicell reported quarterly EPS of $0.94, beating estimates of $0.47, while revenue rose 7.4% year over year to $312.21 million. Shares opened at $33.08, near the lower end of their 52-week range of $29.06 to $55.00.

Deutsche Bank AG acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 49,147 shares of the company's stock, valued at approximately $2,041,000. Deutsche Bank AG owned about 0.11% of Omnicell as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the business. Dana Investment Advisors Inc. bought a new stake in shares of Omnicell in the 4th quarter worth about $3,445,000. Bank of America Corp DE boosted its stake in shares of Omnicell by 31.3% during the 1st quarter. Bank of America Corp DE now owns 580,875 shares of the company's stock worth $19,390,000 after purchasing an additional 138,537 shares during the period. Jackson Creek Investment Advisors LLC bought a new position in Omnicell during the 4th quarter valued at about $2,022,000. Dimensional Fund Advisors LP grew its holdings in Omnicell by 6.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company's stock valued at $81,791,000 after purchasing an additional 137,834 shares during the last quarter. Finally, WCM Investment Management LLC purchased a new stake in Omnicell in the 1st quarter worth about $9,783,000. Institutional investors own 97.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on OMCL shares. Zacks Research lowered Omnicell from a "hold" rating to a "strong sell" rating in a research report on Friday, August 7th. Piper Sandler reiterated an "overweight" rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. KeyCorp reissued an "overweight" rating on shares of Omnicell in a research note on Monday. Wall Street Zen upgraded Omnicell from a "buy" rating to a "strong-buy" rating in a report on Sunday, May 10th. Finally, Wells Fargo & Company cut their price objective on Omnicell from $55.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday, July 31st. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $57.86.

Omnicell Stock Performance

Shares of NASDAQ:OMCL opened at $33.08 on Friday. The firm's 50 day simple moving average is $39.80 and its 200-day simple moving average is $39.33. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. Omnicell, Inc. has a one year low of $29.06 and a one year high of $55.00. The firm has a market cap of $1.50 billion, a PE ratio of 39.38, a price-to-earnings-growth ratio of 0.84 and a beta of 0.98.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.47. The company had revenue of $312.21 million for the quarter, compared to analysts' expectations of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.Omnicell's revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, equities analysts predict that Omnicell, Inc. will post 1.41 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source